Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $125K | $125K | $125K | — | — | — |
| Revenue growth | — | 0.0% | 0.0% | — | — | — |
| Operating income | -$13.8M | -$25.7M | -$34.7M | -$38.4M | -$33.4M | -$48.3M |
| Operating margin | -11048.0% | -20580.8% | -27777.6% | — | — | — |
| Net income | -$17.7M | -$36.1M | -$18.8M | -$37.9M | -$55.2M | -$38.2M |
| Net margin | -14144.0% | -28899.2% | -15035.2% | — | — | — |
| EPS (diluted) | -$1.52 | -$1.91 | -$0.65 | -$1.31 | -$1.74 | -$0.72 |
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$9.07M | -$22.2M | -$31.4M | -$34.2M | -$27.0M | -$38.3M |
| Capital expenditures | $1.48M | $1.83M | $1.30M | $457K | $16.0K | $587K |
| Free cash flow | -$10.5M | -$24.1M | -$32.7M | -$34.7M | -$27.0M | -$38.9M |
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $35.1M | $82.6M | $70.1M | $35.4M | $103M | $120M |
| Total assets | $38.3M | $89.2M | $77.7M | $41.2M | $107M | $125M |
| Total liabilities | $12.8M | $25.1M | $30.0M | $28.5M | $40.5M | $73.3M |
| Long-term debt | $483K | $560K | — | $11.6M | $1.73M | — |
| Shareholders' equity | -$23.6M | $64.1M | $47.7M | $12.7M | $66.3M | $51.9M |
| Retained earnings | -$44.2M | -$80.3M | -$99.1M | -$137M | -$192M | -$230M |
| Shares (wtd avg diluted) | 11.6M | 18.9M | 28.8M | 28.9M | 31.7M | 53.0M |
Every figure is extracted from Candel Therapeutics, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.